Works [9] et al. proved through in vitro studies that lenalidomide promoted the secretion of cytokines such as IFN-γ, IL-2 and TNF-α in anti-BCMA CAR-T, and enhanced the function of anti-BCMA CAR-T cells in a dose-dependent manner, which led to increased tumor clearance. The gene discussed is TNFRSF17; the disease is neoplasm.